Showing 5511-5520 of 5685 results for "".
- Neuro-Optometric Rehabilitation Association Names New Members to its Advisory Boardhttps://modernod.com/news/nuero-optometric-rehabilitation-association-names-new-members-to-its-advisory-board/2479836/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the addition of six new members to its Advisory Board, at the Association’s 27th Annual Conference in St. Louis. “Our new Advisory Board members bring a rich mix of backgrounds and experiences that w
- Compulink Showcases Eyecare Specific Artificial Intelligence EHR Solution at Vision Expo West 2018https://modernod.com/news/compulink-showcases-eyecare-specific-artificial-intelligence-ehr-solution-at-vision-expo-west-2018/2479838/Compulink Healthcare Solutions will demonstrate the latest enhancements to Eyecare Advantage at this week’s International Vision Expo West. This includes new artificial intelligence (AI)-enabled features in a release its calling Advantage SMART Practice. Adva
- National Industries for the Blind Announces New Strategic Alliancehttps://modernod.com/news/national-industries-for-the-blind-announces-new-strategic-alliance/2479842/National Industries for the Blind (NIB) announced a new strategic alliance with the William L. Hudson BVI Workforce Innovation Center to deliver world-class training and professional development for people who are blind. The William L. Hudson BVI Workforce Innovation Center, located in
- ASCRS Releases Preliminary CyPass Withdrawal Consensus Statementhttps://modernod.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. To
- Neurolens Appoints Davis Corley Chief Executive Officerhttps://modernod.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/Neurolens announced that its board of directors has named Davis Corley chief executive officer (CEO). Mr. Corley was a co-founder of neurolens in 2012 and has served as president since 2014, a role that he will continue. “Since day one, Davis has led the dev
- Ellex 2RT Retinal Rejuvenation Effective for Select Cases of Intermediate AMDhttps://modernod.com/news/ellex-2rt-retinal-rejuvenation-effective-for-select-cases-of-intermediate-amd/2479852/Ellex Medical Lasers Limited announced the results of the Ellex 2RT Laser Intervention in Age-Related Macular Degeneration (LEAD) multicenter clinical trial. The results of the trial were published in Ophthalmology. According to researchers involved in the LEAD trial, Ellex’s 2RT
- Heidelberg Engineering Announces CE Mark Approval of Anterionhttps://modernod.com/news/heidelberg-engineering-announces-the-ce-marking-of-anterion/2479854/Heidelberg Engineering announced the CE-marking of Anterion, a platform designed to transform anterior segment diagnostics and workflow. The new Anterion provides anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solutio
- Optos Launches Monaco Ultra-Widefield Retinal Imaging Systemhttps://modernod.com/news/optos-launches-monaco-ultra-widefield-retinal-imaging-system/2479855/Optos has launched Monaco, its latest ultra-widefield device to the European ophthalmic market. Monaco is the only ultra-widefield retinal imaging system with integrated Optical Coherence Tomography (OCT), according to Optos. It produces a 200° single-capture optomap image in less than hal
- MacuLogix Launches the AdaptDx in Europehttps://modernod.com/news/maculogix-launches-the-adaptdx-in-europe-at-euretina/2479856/MacuLogix will launch the AdaptDx in Europe during its debut at the European Society of Retina Specialists (EURETINA) annual congress
- Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-enrolls-first-patient-in-phase-1-clinical-trial-evaluating-thr-687-for-treatment-of-dme/2479860/Oxurion announced the enrollment of the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME). THR-687 is a novel pan-RGD integrin antagoni